Liou M.-C.KAI-HSIN LINMENG-YAO LUDONG-TSAMN LIN2020-12-162020-12-1620020929-6646https://www.scopus.com/inward/record.uri?eid=2-s2.0-0036657399&partnerID=40&md5=9405be4ec192dd256014d0995567e503https://scholars.lib.ntu.edu.tw/handle/123456789/526477The effective treatment of childhood malignancies has increased the importance of early detection and treatment of second malignant neoplasms. Anticancer drugs may also be leukemogenic agents, by the same mechanisms that kill cancer cells. We report the case of a 10-year-old boy who had received radiotherapy and chemotherapy for the treatment of Ewing's sarcoma and developed acute lymphoblastic leukemia 22 months after the diagnosis of primary malignancy. Although chemotherapy is well known to potentiate the development of second acute nonlymphocytic leukemia, the pathogenic factors leading to second acute lymphoblastic leukemia remain obscure.Acute lymphoblastic leukemia; Second malignant neoplasm[SDGs]SDG3antineoplastic agent; asparaginase; CD15 antigen; CD19 antigen; CD2 antigen; CD20 antigen; CD33 antigen; CD34 antigen; CD7 antigen; common acute lymphoblastic leukemia antigen; cyclophosphamide; cytarabine; dactinomycin; epirubicin; etoposide; HLA DR antigen; microsomal aminopeptidase; prednisolone; vincristine; acute lymphoblastic leukemia; article; cancer chemotherapy; cancer diagnosis; case report; childhood cancer; early diagnosis; Ewing sarcoma; human; karyotyping; leukemogenesis; male; pathogenesis; school child; second cancer; Bone Neoplasms; Child; Humans; Leukemia, Lymphocytic, Acute, L1; Male; Neoplasms, Second Primary; Sarcoma, Ewing'sjournal article123533432-s2.0-0036657399